Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ZLAB
ZLAB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ZLAB News
Oncolytics Biotech Receives FDA Fast Track Designation
Feb 05 2026
PRnewswire
FDA Accelerates Oncology Drug Approvals, Boosting Market Potential
Feb 05 2026
Newsfilter
ClearBridge International Growth Strategy Underperforms in Q4 2025
Feb 04 2026
seekingalpha
Oversold Stocks in Healthcare Sector Present Buying Opportunities
Feb 03 2026
Benzinga
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
Jan 14 2026
seekingalpha
Seeking Alpha Releases Q4 Stock Ratings, Micron and Others Rated Strong Buy
Jan 12 2026
seekingalpha
Zai Lab Receives NMPA Approval for AUGTYRO™ in NTRK-Positive Solid Tumors
Jan 06 2026
Newsfilter
Zai Lab Receives NMPA Approval for AUGTYRO in NTRK-Positive Solid Tumors
Jan 06 2026
Businesswire
Zai Lab to Participate in 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Jan 05 2026
Businesswire
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
Jan 05 2026
NASDAQ.COM
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Zai Lab Receives NMPA Approval for COBENFY to Treat Schizophrenia
Dec 24 2025
NASDAQ.COM
Reviva Pharmaceuticals Plans Second Phase 3 Trial for Brilaroxazine in 2026 Following FDA Feedback
Dec 23 2025
Benzinga
Zai Lab Receives NMPA Approval for COBENFY to Treat Schizophrenia
Dec 23 2025
Businesswire
Zai Lab Updates Three Medicines in China's National Reimbursement Drug List
Dec 07 2025
Newsfilter
Zai Lab Secures Inclusion of Six Medicines in 2025 NRDL
Dec 07 2025
Businesswire
Show More News
